Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of rare cardiovascular disease programs focused on Friedreich’s ataxia (FA) cardiomyopathy and arrhythmogenic cardiomyopathy (ACM).
Role Summary
The Graduate intern will have the opportunity to make significant contributions to Lexeo’s portfolio management systems and strategy. With multiple interim data readouts expected in 2026, the Intern will help to shape planning, resourcing, budgeting and risk management as these complex gene therapy programs advance. Over the course of the summer, the intern will work to develop and improve systems for analyzing program data and metrics to better identify opportunities for improvement, providing recommendations and implementing new systems and/or strategies for cycle time improvement, clinical trial management and oversight and program execution.
Primary Responsibilities
Conduct analyses of program and portfolio-level metrics (e.g., cycle times, enrollment curves, study performance) against internal benchmarks and industry standards. Identify opportunities for improvement and develop actionable recommendations.
Design and implement more efficient, automated approaches to data tracking and reporting. Evaluate opportunities to reduce manual processes, including leveraging tools, AI, or integrations.
Build intuitive dashboards at both the study and portfolio level. Select appropriate visualizations to support decision-making (e.g., trend analysis, variance tracking, forecasting).
Support improvements in how teams manage and communicate work, including optimizing meeting structures (e.g., agenda-driven meetings, documentation of decisions and action items) and enhancing use of collaboration tools such as Microsoft Teams.
Partner closely with Program & Portfolio Management, Finance, Clinical Development, Regulatory Affairs, and Technical Development teams to ensure alignment and effective execution across a growing global footprint (including expansion into Europe and Brazil).
Translate complex data into clear, concise insights for stakeholders. Support communication of findings, recommendations, and progress to leadership.
Required Skills & Qualifications
- Currently pursuing an MBA or Master’s degree, with 2–4+ years of prior professional experience (e.g., consulting, analytics, program management, or biopharmaceuticals)
- Strong analytical mindset with demonstrated ability to synthesize complex datasets into actionable insights
- Advanced proficiency in Excel (modeling, scenario analysis, trackers) and experience with data visualization tools (e.g., Tableau, Spotfire, Power BI)
- Demonstrated interest in data analytics, automation, and/or AI applications in a business or healthcare context
- Highly organized with strong project management skills and attention to detail
- Self-starter who is comfortable operating with limited direction and proactively bringing forward ideas and solutions
- Strong interpersonal and communication skills with the ability to work effectively across functions
- Interest in healthcare, biotechnology, or clinical research (prior experience is a plus, but not required)
Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
Top Skills
What We Do
LEXEO Therapeutics is a New York City-based, clinical-stage gene therapy company focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. LEXEO’s foundational science stems from partnerships and exclusive licenses with leading academic laboratories at Weill Cornell Medical College and the University of California, San Diego, two preeminent institutions on the cutting edge of gene therapy research. LEXEO is advancing a deep and diverse pipeline of AAV-based gene therapy candidates in rare cardiovascular diseases, APOE4-associated Alzheimer’s disease, and CLN2 Batten disease, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.
